Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC9A1 | P19634 | 1/20 | 0.60 |
| ▸ | FFAR1 | O14842 | 6/20 | 0.59 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.51 |
| ▸ | KDM1A | O60341 | 2/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1839154 | 1.00 | SLC9A1 (0.60) | SLC9A1FFAR1HRH3KDM1ASIGMAR1 | |
| SCHEMBL14550059 | 1.00 | SLC9A1 (0.60) | SLC9A1FFAR1HRH3KDM1ASIGMAR1 | |
| SCHEMBL1839151 | 1.00 | SLC9A1 (0.60) | SLC9A1FFAR1HRH3KDM1ASIGMAR1 | |
| SCHEMBL1019425 | 1.00 | SLC9A1 (0.60) | SLC9A1FFAR1HRH3KDM1ASIGMAR1 | |
| SCHEMBL4209759 | 1.00 | SLC9A1 (0.60) | SLC9A1FFAR1HRH3KDM1ASIGMAR1 | |
| SCHEMBL34467094 | 0.87 | MAPT (0.53) | SLC9A1FFAR1MAPTGAAHPGD | |
| SCHEMBL16232154 | 0.84 | SLC9A1 (0.60) | SLC9A1HRH3KDM1ASIGMAR1MAPT | |
| SCHEMBL17189659 | 0.84 | SLC9A1 (0.65) | SLC9A1FFAR1HRH3KDM1ASIGMAR1 | |
| SCHEMBL13976000 | 0.84 | SLC9A1 (0.65) | SLC9A1FFAR1HRH3KDM1ASIGMAR1 | |
| SCHEMBL12765396 | 0.84 | SLC9A1 (0.60) | SLC9A1HRH3KDM1ASIGMAR1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2729447-B1 | POSITIVE ALLOSTERIC MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTOR | H LUNDBECK AS (DK) | 2018-05-30 | — | — | EP | claimed |
| US-20150315130-A1 | New positive allosteric modulators of nicotinic acetylcholine receptor | H. LUNDBECK A/S (DK) | 2015-11-05 | — | — | US | claimed |
| EP-2928860-A1 | NEW POSITIVE ALLOSTERIC MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTOR | H. Lundbeck A/S (DK) | 2015-10-14 | — | — | EP | claimed |
| WO-2014090731-A1 | NEW POSITIVE ALLOSTERIC MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTOR | H. LUNDBECK A/S (DK) | 2014-06-19 | — | — | WO | claimed |
| EP-2729447-A1 | POSITIVE ALLOSTERIC MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTOR | H. Lundbeck A/S (DK) | 2014-05-14 | — | — | EP | claimed |
| US-20140044806-A1 | NEW POSITIVE ALLOSTERIC MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTOR | H. LUNDBECK A/S (DK) | 2014-02-13 | — | — | US | claimed |
| US-8598213-B2 | Positive allosteric modulators of nicotinic acetylcholine receptor | H. LUNDBECK A/S (DK) | 2013-12-03 | — | — | US | claimed |
| WO-2013007621-A1 | POSITIVE ALLOSTERIC MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTOR | H. LUNDBECK A/S (DK) | 2013-01-17 | — | — | WO | claimed |
| US-20130012530-A1 | New Positive allosteric modulators of nicotinic acetylcholine receptor | H. LUNDBECK A/S (DK) | 2013-01-10 | — | — | US | claimed |
| EP-4709708-A1 | NOVEL CARBOXAMIDE DERIVATIVES | ANGELINI PHARMA S.P.A. (IT) | 2026-03-18 | — | — | EP | disclosed |
| US-20250051309-A1 | MK2 INHIBITORS AND METHODS OF MAKING AND USING THE SAME | GILEAD SCIENCES, INC. | 2025-02-13 | — | — | US | disclosed |
| WO-2024233603-A1 | NOVEL CARBOXAMIDE DERIVATIVES | ICAGEN, LLC (US) | 2024-11-14 | — | — | WO | disclosed |
| US-11773068-B2 | KDM1A inhibitors for the treatment of disease | IMAGO BIOSCIENCES, INC. (US) | 2023-10-03 | — | — | US | disclosed |
| US-11230534-B2 | KDM1A inhibitors for the treatment of disease | IMAGO BIOSCIENCES, INC. (US) | 2022-01-25 | — | — | US | disclosed |
| WO-2013007621-A1 | POSITIVE ALLOSTERIC MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTOR | H. LUNDBECK A/S (DK) | 2013-01-17 | — | — | WO | disclosed |
| US-20130012530-A1 | New Positive allosteric modulators of nicotinic acetylcholine receptor | H. LUNDBECK A/S (DK) | 2013-01-10 | — | — | US | disclosed |
| US-20130012530-A1 | New Positive allosteric modulators of nicotinic acetylcholine receptor | H. LUNDBECK A/S (DK) | 2013-01-10 | — | — | US | disclosed |
| US-20130012530-A1 | New Positive allosteric modulators of nicotinic acetylcholine receptor | H. LUNDBECK A/S (DK) | 2013-01-10 | — | — | US | disclosed |
| US-20120202794-A1 | COMPOUNDS | PHARMASSET, INC. (US) | 2012-08-09 | — | — | US | disclosed |
| WO-2012103113-A1 | PYRAZINE AND IMIDAZOLIDINE DERIVATIVES AND THEIR USES TO TREAT HEPATITIS C | GILEAD PHARMASSET, LLC (US) | 2012-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150315130-A1 | New positive allosteric modulators of nicotinic acetylcholine receptor | CHRNG, CHRNA7, CHRNA1 | SLC9A1 2163/4885FFAR1 303/4885HRH3 649/4885 |
| US-20140044806-A1 | NEW POSITIVE ALLOSTERIC MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTOR | CHRNG, CHRNA7, CHRNA1 | SLC9A1 2163/4885FFAR1 303/4885HRH3 649/4885 |
| US-20120202794-A1 | COMPOUNDS | HAVCR2, MAVS, GOT2 | SLC9A1 4172/4885FFAR1 2319/4885HRH3 3787/4885 |
| US-20130012530-A1 | New Positive allosteric modulators of nicotinic acetylcholine receptor | CHRNG, CHRNA7, CHRNA1 | SLC9A1 2163/4885FFAR1 303/4885HRH3 649/4885 |
| US-20250051309-A1 | MK2 INHIBITORS AND METHODS OF MAKING AND USING THE SAME | DUSP2, MKNK2, DUSP22 | SLC9A1 4335/4885FFAR1 4314/4885HRH3 2642/4885 |
| US-11230534-B2 | KDM1A inhibitors for the treatment of disease | KDM1B, KDM1A, KDM2A | SLC9A1 3240/4885FFAR1 4334/4885HRH3 1345/4885 |
| US-11773068-B2 | KDM1A inhibitors for the treatment of disease | KDM1B, KDM1A, KDM2A | SLC9A1 3240/4885FFAR1 4334/4885HRH3 1345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.